Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Injectable Aesthetics
    • Dermatological Skincare
    • Therapeutic Dermatology
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2024
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Podcasts
  • Innovation
    • Skin Science by Galderma
    • Bringing innovation to life
    • Partnering
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • For society
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Home
  • Investors

Cetaphil Celebrates Global Initiative Highlighting Sensitive Skin with a Month of Skin Science Education

Press release

Cetaphil® unveils digital AI skin analysis tool to empower and educate users with sensitive skin

Press release

Cetaphil raises awareness of the connection between clothing and sensitive skin

Press release

Galderma Launches Cutting-Edge Formulation With Alastin Skincare® Resurface Skin Polish Developed To Uncover Visibly Glowing Skin

Press release

"The Full Spectrum of Dermatology: A Diverse And Inclusive Atlas" Launches New, Free Online Image Gallery

Press release

Differin® Expands Portfolio with the Addition of Two New Facial Skincare Products

Press release

Leading Acne Brand Launches First-Ever ​Retinoid Education Week

Press release

New Phase 4 OSCAR Trial Data Showed that Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Decreased Acne Lesions Therefore Reducing the Risk of Scars in Moderate-to-Severe Acne Patients

Press release

Galderma Announces Results of ALAMO: A Real-World, Phase 4 Study Demonstrating Efficacy and Safety of Epiduo® Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5% Plus Oral Doxycycline 200 mg in Treating Severe Inflammatory Acne

Press release

Nestlé Skin Health Announces the FDA Approval of Restylane® Lyft for Hands, the First and Only Hyaluronic Acid (HA) Dermal Filler for Use in the Back of Hands

Press release

Pagination

  • Previous page Previous Page
  • Next page Next Page
Subscribe to U.S. release
  1. Home
  2. U.S. release

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2025

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back